
OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
CAR immune cells: design principles, resistance and the next generation
Louai Labanieh, Crystal L. Mackall
Nature (2023) Vol. 614, Iss. 7949, pp. 635-648
Closed Access | Times Cited: 338
Louai Labanieh, Crystal L. Mackall
Nature (2023) Vol. 614, Iss. 7949, pp. 635-648
Closed Access | Times Cited: 338
Showing 26-50 of 338 citing articles:
Targeted nonviral delivery of genome editors in vivo
Connor A. Tsuchida, Kevin Wasko, Jennifer Hamilton, et al.
Proceedings of the National Academy of Sciences (2024) Vol. 121, Iss. 11
Open Access | Times Cited: 16
Connor A. Tsuchida, Kevin Wasko, Jennifer Hamilton, et al.
Proceedings of the National Academy of Sciences (2024) Vol. 121, Iss. 11
Open Access | Times Cited: 16
Engineering immune-evasive allogeneic cellular immunotherapies
Karen E. Martin, Quirin Hammer, Karlo Perica, et al.
Nature reviews. Immunology (2024) Vol. 24, Iss. 9, pp. 680-693
Closed Access | Times Cited: 16
Karen E. Martin, Quirin Hammer, Karlo Perica, et al.
Nature reviews. Immunology (2024) Vol. 24, Iss. 9, pp. 680-693
Closed Access | Times Cited: 16
Novel strategies to manage CAR-T cell toxicity
Arthur Mulvey, Lionel Trueb, George Coukos, et al.
Nature Reviews Drug Discovery (2025)
Closed Access | Times Cited: 4
Arthur Mulvey, Lionel Trueb, George Coukos, et al.
Nature Reviews Drug Discovery (2025)
Closed Access | Times Cited: 4
Antigen experience history directs distinct functional states of CD8+ CAR T cells during the antileukemia response
Kole DeGolier, Etienne Danis, Marc D’Antonio, et al.
Nature Immunology (2025) Vol. 26, Iss. 1, pp. 68-81
Open Access | Times Cited: 3
Kole DeGolier, Etienne Danis, Marc D’Antonio, et al.
Nature Immunology (2025) Vol. 26, Iss. 1, pp. 68-81
Open Access | Times Cited: 3
Inhalable nanovesicles loaded with a STING agonist enhance CAR-T cell activity against solid tumors in the lung
Tianchuan Zhu, Yuchen Xiao, Zhenxing Chen, et al.
Nature Communications (2025) Vol. 16, Iss. 1
Open Access | Times Cited: 3
Tianchuan Zhu, Yuchen Xiao, Zhenxing Chen, et al.
Nature Communications (2025) Vol. 16, Iss. 1
Open Access | Times Cited: 3
Boosting CAR-T cell therapy through vaccine synergy
Yan-Ruide Li, Zibai Lyu, Xinyuan Shen, et al.
Trends in Pharmacological Sciences (2025)
Open Access | Times Cited: 2
Yan-Ruide Li, Zibai Lyu, Xinyuan Shen, et al.
Trends in Pharmacological Sciences (2025)
Open Access | Times Cited: 2
CD133+PD-L1+ cancer cells confer resistance to adoptively transferred engineered macrophage-based therapy in melanoma
Jiaojiao Xu, Zhe Li, Qinli Tong, et al.
Nature Communications (2025) Vol. 16, Iss. 1
Open Access | Times Cited: 2
Jiaojiao Xu, Zhe Li, Qinli Tong, et al.
Nature Communications (2025) Vol. 16, Iss. 1
Open Access | Times Cited: 2
CAR T cells for treating autoimmune diseases
Ulrich Blache, Sandy Tretbar, Ulrike Koehl, et al.
RMD Open (2023) Vol. 9, Iss. 4, pp. e002907-e002907
Open Access | Times Cited: 39
Ulrich Blache, Sandy Tretbar, Ulrike Koehl, et al.
RMD Open (2023) Vol. 9, Iss. 4, pp. e002907-e002907
Open Access | Times Cited: 39
Mechanisms of Resistance and Treatment of Relapse after CAR T-cell Therapy for Large B-cell Lymphoma and Multiple Myeloma
Kai Rejeski, Michael D. Jain, Eric L. Smith
Transplantation and Cellular Therapy (2023) Vol. 29, Iss. 7, pp. 418-428
Open Access | Times Cited: 31
Kai Rejeski, Michael D. Jain, Eric L. Smith
Transplantation and Cellular Therapy (2023) Vol. 29, Iss. 7, pp. 418-428
Open Access | Times Cited: 31
Latent human herpesvirus 6 is reactivated in CAR T cells
Caleb A. Lareau, Yajie Yin, Katie Maurer, et al.
Nature (2023) Vol. 623, Iss. 7987, pp. 608-615
Open Access | Times Cited: 31
Caleb A. Lareau, Yajie Yin, Katie Maurer, et al.
Nature (2023) Vol. 623, Iss. 7987, pp. 608-615
Open Access | Times Cited: 31
Reprogramming T cell differentiation and exhaustion in CAR-T cell therapy
Yannick Bulliard, Börje S. Andersson, Mehmet A. Baysal, et al.
Journal of Hematology & Oncology (2023) Vol. 16, Iss. 1
Open Access | Times Cited: 28
Yannick Bulliard, Börje S. Andersson, Mehmet A. Baysal, et al.
Journal of Hematology & Oncology (2023) Vol. 16, Iss. 1
Open Access | Times Cited: 28
CAR-T cell therapy for hematological malignancies: History, status and promise
Chao Wang, Jianpeng Wang, Shusheng Che, et al.
Heliyon (2023) Vol. 9, Iss. 11, pp. e21776-e21776
Open Access | Times Cited: 24
Chao Wang, Jianpeng Wang, Shusheng Che, et al.
Heliyon (2023) Vol. 9, Iss. 11, pp. e21776-e21776
Open Access | Times Cited: 24
Biomaterials to enhance adoptive cell therapy
Noah Eckman, Anahita Nejatfard, Romola Cavet, et al.
Nature Reviews Bioengineering (2024) Vol. 2, Iss. 5, pp. 408-424
Closed Access | Times Cited: 14
Noah Eckman, Anahita Nejatfard, Romola Cavet, et al.
Nature Reviews Bioengineering (2024) Vol. 2, Iss. 5, pp. 408-424
Closed Access | Times Cited: 14
Group 3 innate lymphoid cells in intestinal health and disease
Veronika Horn, Gregory F. Sonnenberg
Nature Reviews Gastroenterology & Hepatology (2024) Vol. 21, Iss. 6, pp. 428-443
Closed Access | Times Cited: 14
Veronika Horn, Gregory F. Sonnenberg
Nature Reviews Gastroenterology & Hepatology (2024) Vol. 21, Iss. 6, pp. 428-443
Closed Access | Times Cited: 14
Potential and pitfalls of repurposing the CAR-T cell regimen for the treatment of autoimmune disease
Andrea R. Daamen, Peter E. Lipsky
Annals of the Rheumatic Diseases (2024) Vol. 83, Iss. 6, pp. 696-699
Closed Access | Times Cited: 14
Andrea R. Daamen, Peter E. Lipsky
Annals of the Rheumatic Diseases (2024) Vol. 83, Iss. 6, pp. 696-699
Closed Access | Times Cited: 14
Toxicities, intensive care management, and outcome of chimeric antigen receptor T cells in adults: an update
Mathieu Bellal, Jolan Malherbe, Gandhi Damaj, et al.
Critical Care (2024) Vol. 28, Iss. 1
Open Access | Times Cited: 12
Mathieu Bellal, Jolan Malherbe, Gandhi Damaj, et al.
Critical Care (2024) Vol. 28, Iss. 1
Open Access | Times Cited: 12
SMYD5 methylation of rpL40 links ribosomal output to gastric cancer
Ju-Hyung Park, Jibo Wu, Krzysztof J. Szkop, et al.
Nature (2024) Vol. 632, Iss. 8025, pp. 656-663
Closed Access | Times Cited: 12
Ju-Hyung Park, Jibo Wu, Krzysztof J. Szkop, et al.
Nature (2024) Vol. 632, Iss. 8025, pp. 656-663
Closed Access | Times Cited: 12
Genetic engineering of regulatory T cells for treatment of autoimmune disorders including type 1 diabetes
Karoliina Tuomela, Megan K. Levings
Diabetologia (2024) Vol. 67, Iss. 4, pp. 611-622
Open Access | Times Cited: 11
Karoliina Tuomela, Megan K. Levings
Diabetologia (2024) Vol. 67, Iss. 4, pp. 611-622
Open Access | Times Cited: 11
Eosinophil‐Activating Semiconducting Polymer Nanoparticles for Cancer Photo‐Immunotherapy
Chi Zhang, Jingsheng Huang, Mengke Xu, et al.
Angewandte Chemie International Edition (2024) Vol. 63, Iss. 30
Closed Access | Times Cited: 11
Chi Zhang, Jingsheng Huang, Mengke Xu, et al.
Angewandte Chemie International Edition (2024) Vol. 63, Iss. 30
Closed Access | Times Cited: 11
Immunotherapy in Sarcoma: Current Data and Promising Strategies
Georgina Wood, Christian F. Meyer, Florent Petitprez, et al.
American Society of Clinical Oncology Educational Book (2024) Vol. 44, Iss. 3
Closed Access | Times Cited: 11
Georgina Wood, Christian F. Meyer, Florent Petitprez, et al.
American Society of Clinical Oncology Educational Book (2024) Vol. 44, Iss. 3
Closed Access | Times Cited: 11
Fratricide-resistant CD7-CAR T cells in T-ALL
Bernice Oh, Noriko Shimasaki, Elaine Coustan‐Smith, et al.
Nature Medicine (2024)
Closed Access | Times Cited: 11
Bernice Oh, Noriko Shimasaki, Elaine Coustan‐Smith, et al.
Nature Medicine (2024)
Closed Access | Times Cited: 11
An engineering strategy to target activated EGFR with CAR T cells
Markus Dobersberger, Delia Sumesgutner, Charlotte U. Zajc, et al.
Cell Reports Methods (2024) Vol. 4, Iss. 4, pp. 100728-100728
Open Access | Times Cited: 10
Markus Dobersberger, Delia Sumesgutner, Charlotte U. Zajc, et al.
Cell Reports Methods (2024) Vol. 4, Iss. 4, pp. 100728-100728
Open Access | Times Cited: 10
Advancements in γδT cell engineering: paving the way for enhanced cancer immunotherapy
Megan Yuan, Wenjun Wang, Isobel Hawes, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 10
Megan Yuan, Wenjun Wang, Isobel Hawes, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 10
Enhancing pediatric access to cell and gene therapies
Crystal L. Mackall, Catherine M. Bollard, Nancy L. Goodman, et al.
Nature Medicine (2024) Vol. 30, Iss. 7, pp. 1836-1846
Closed Access | Times Cited: 10
Crystal L. Mackall, Catherine M. Bollard, Nancy L. Goodman, et al.
Nature Medicine (2024) Vol. 30, Iss. 7, pp. 1836-1846
Closed Access | Times Cited: 10
GLUT1 overexpression in CAR-T cells induces metabolic reprogramming and enhances potency
Justin Arredondo-Guerrero, Dorota D. Klysz, Yiyun Chen, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 10
Justin Arredondo-Guerrero, Dorota D. Klysz, Yiyun Chen, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 10